JP5167155B2 - ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法 - Google Patents

ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法 Download PDF

Info

Publication number
JP5167155B2
JP5167155B2 JP2008558560A JP2008558560A JP5167155B2 JP 5167155 B2 JP5167155 B2 JP 5167155B2 JP 2008558560 A JP2008558560 A JP 2008558560A JP 2008558560 A JP2008558560 A JP 2008558560A JP 5167155 B2 JP5167155 B2 JP 5167155B2
Authority
JP
Japan
Prior art keywords
peptide
peptides
receptor
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008558560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529333A (ja
JP2009529333A5 (https=
Inventor
ワディー アラップ
レナータ パスカリーニ
ミハイル コローニン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2009529333A publication Critical patent/JP2009529333A/ja
Publication of JP2009529333A5 publication Critical patent/JP2009529333A5/ja
Application granted granted Critical
Publication of JP5167155B2 publication Critical patent/JP5167155B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2008558560A 2006-03-09 2007-03-09 ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法 Expired - Fee Related JP5167155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78089306P 2006-03-09 2006-03-09
US60/780,893 2006-03-09
PCT/US2007/063736 WO2007104062A2 (en) 2006-03-09 2007-03-09 Compositions and methods based on peptide binding profiling

Publications (3)

Publication Number Publication Date
JP2009529333A JP2009529333A (ja) 2009-08-20
JP2009529333A5 JP2009529333A5 (https=) 2011-06-30
JP5167155B2 true JP5167155B2 (ja) 2013-03-21

Family

ID=38475889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558560A Expired - Fee Related JP5167155B2 (ja) 2006-03-09 2007-03-09 ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法

Country Status (6)

Country Link
US (3) US7781565B2 (https=)
EP (2) EP2002036A4 (https=)
JP (1) JP5167155B2 (https=)
AU (1) AU2007222991A1 (https=)
CA (1) CA2645277A1 (https=)
WO (1) WO2007104062A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9575070B2 (en) * 2001-12-04 2017-02-21 Wayne State University Neoepitope detection of disease using protein arrays
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
ITTO20060852A1 (it) * 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
US8722851B2 (en) * 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
JP2009126811A (ja) * 2007-11-22 2009-06-11 Kyoto Univ 合成ペプチド及びその利用
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
FR2961814B1 (fr) * 2010-06-29 2014-09-26 Isp Investments Inc Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
US20120055055A1 (en) 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
EP2444101A1 (en) * 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
WO2012170975A1 (en) * 2011-06-10 2012-12-13 The United States Of America As Representrd By The Secretary Of The Navy Nano-encapsulated therapeutics for controlled treatment of infection and other diseases
CN103764668B (zh) * 2011-07-09 2016-08-17 加利福尼亚大学董事会 白血病干细胞靶向配体及应用方法
EP2756002A4 (en) * 2011-09-16 2015-04-08 Univ Texas COMPOSITIONS AND METHODS RELATED TO THE REPAIR OF DNA DAMAGES
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
EP2838547B1 (en) * 2012-04-16 2019-09-04 Lubrizol Advanced Materials, Inc. Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
CN103387603B (zh) * 2012-05-08 2015-07-15 复旦大学 一种rtn4b相关多肽及其制备与应用
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
DK3456734T3 (da) 2012-10-04 2022-04-19 Res Found Dev Serinproteasemolekyler og behandlinger
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
AU2014306592B2 (en) 2013-08-14 2019-04-04 Bristol-Myers Squibb Company Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
CN103804470B (zh) * 2014-01-22 2016-08-17 深圳市奥尼克斯基因技术有限公司 一种特异性靶向肿瘤淋巴管的新型多肽tmvp1的获得及应用
CA2993823C (en) 2015-07-28 2024-01-02 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
JP6839447B2 (ja) * 2015-10-01 2021-03-10 国立大学法人 新潟大学 胆道癌に特異的な集積性を有するペプチド及びその使用
CA3014921A1 (en) 2016-02-16 2017-08-24 Research Development Foundation Sortase-modified molecules and uses thereof
WO2018102762A1 (en) 2016-12-02 2018-06-07 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372473B1 (en) * 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
EP2028187A1 (en) 2000-09-08 2009-02-25 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
US20040048243A1 (en) 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7718776B2 (en) * 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
EP1369482A1 (en) 2002-06-07 2003-12-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target genes for the diagnosis and treatment of cancer
DK1709081T3 (da) * 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
EP1755686A2 (en) * 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
WO2006010070A2 (en) * 2004-07-10 2006-01-26 Board Of Regents, The University Of Texas System Compositions and methods related to peptides that selectively bind leukemia cells
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY

Also Published As

Publication number Publication date
US7781565B2 (en) 2010-08-24
US20070248952A1 (en) 2007-10-25
JP2009529333A (ja) 2009-08-20
EP2002036A4 (en) 2010-01-27
AU2007222991A1 (en) 2007-09-13
EP2338898A1 (en) 2011-06-29
CA2645277A1 (en) 2007-09-13
WO2007104062A8 (en) 2008-10-09
AU2007222991A8 (en) 2011-03-10
US20100298233A1 (en) 2010-11-25
EP2002036A2 (en) 2008-12-17
WO2007104062A3 (en) 2008-11-27
AU2007222991A2 (en) 2009-03-12
WO2007104062A2 (en) 2007-09-13
US20130089498A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
JP5167155B2 (ja) ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
US12612621B2 (en) Methods of selecting binding reagents
US11549942B2 (en) Methods of assaying proteins
Kolonin et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries
EP1668368B1 (en) Detection of histone modification in cell-free nucleosomes
Raymond et al. Unbiased peptoid combinatorial cell screen identifies plectin protein as a potential biomarker for lung cancer stem cells
Sadeghi et al. Integrative analysis of breast cancer cells reveals an epithelial-mesenchymal transition role in adaptation to acidic microenvironment
Zhang et al. Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library
Nobrega et al. Screening and characterization of novel specific peptides targeting MDA-MB-231 claudin-low breast carcinoma by computer-aided phage display methodologies
Doran et al. A liquid array platform for the multiplexed analysis of synthetic molecule–protein interactions
Sørensen et al. Microselection–affinity selecting antibodies against a single rare cell in a heterogeneous population
Dimastromatteo et al. Target identification, lead discovery, and optimization
Ballard et al. Quantitative PCR-based approach for rapid phage display analysis: a foundation for high throughput vascular proteomic profiling
Park et al. Phage display screen for peptides that bind Bcl-2 protein
US20260126437A1 (en) Systems for characterizing polypeptides
Asar Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptide Ligands
Koivunen Steps toward mapping the human vasculature by phage display
Hu Coupling Synthetic Antibodies with Mass Cytometry Allows the Development of a Highly Tailored, Multi-Parametric Single Cell Analysis Strategy
Bi et al. Detection of breast cancer-related antigens through cDNA phage-displayed protein microarray.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121221

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151228

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees